Compare Pinterest Inc (PINS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Pinterest (PINS) trades at $20.14, down 1.27% amid recent volatility. The stock shows mixed signals with bearish technical indicators but strong fundamental growth, including three consecutive quarterly earnings beats. Recent CFO resignation and insider selling have pressured sentiment, though revenue grew 18% YoY to $4.22B in 2025. Valuation remains elevated with P/E of 59.24, while analyst consensus maintains a Buy rating with $28.69 price target.

Outlook remains cautiously optimistic given strong revenue growth and AI initiatives, but near-term headwinds include leadership transition, competitive pressures, and valuation concerns. The $4B AWS AI partnership signals long-term ambition but increases cost exposure. Current levels offer potential upside to analyst targets if execution improves.

RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.

Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.